

## Retail Market Monitor

Thursday, 03 February 2022

### MONTHLY REVIEW AND OUTLOOK

**REVIEW:** The FSSTI gained 4.0% mom in Jan 22 to 3,249.59. For Jan 22, the index was lifted mainly by the Finance (+8.7% mom), Shipyard (+6.1% mom) and Plantation (+3.6% mom) sectors, but was dragged by the Healthcare (-6.6%), REITs (-5.8% mom) and Technology (-3.9% mom) sectors.

Singapore's industrial production expanded 15.6% yoy (+4.3% mom seasonally adjusted) in Dec 21, surprising market estimates for a milder growth of 12.0% yoy (+0.9% mom). Excluding biomedical manufacturing, industrial production rose 5.0% yoy. Accounting for the latest data, Singapore's industrial production grew 13.2% for the whole of 2021.

Given the strong manufacturing showing in 4Q21, Singapore's 4Q21 and 2021 GDP growth may likely be revised higher. Full-year GDP growth is expected to be upgraded to 7.3% (from MTI's advance estimates of 7.2%) in 2021, while 4Q21 GDP growth may be adjusted upwards to 6.2% yoy (from 5.9% yoy).

For 2022, we keep to our view that Singapore's manufacturing prognosis remains favourable especially given the strong numbers seen to-date. Our outlook is for full-year manufacturing to grow by an average of 4.0% in 2022. This suggests that despite the high-base growth rate seen in 2021, global trade activity is expected to stay buoyant in the new year.

**STRATEGY:** Our top large-cap picks are Yangzijiang, Thai Beverage, SingTel, Aztech, Frasers Centerpoint Trust and Ascendas REIT. As for the small/mid-cap sector, our top picks are BRC Asia and Civmec.

### TOP BUY

Company	Target Price (\$S)	Last Price (\$S)	Return (%)
Yangzijiang	2.00	1.29	55.0
Thai Beverage	0.92	0.655	40.5
SingTel	2.75	2.43	13.2
Aztech	1.55	0.845	83.4
BRC Asia	1.91	1.63	17.2
Civmec	0.98	0.625	56.8

Source: Bloomberg, UOB Kay Hian

\*last price based on closing price on 31 Jan 22

### TOP SELL

Company	Target Price (\$S)	Last Price (\$S)	Return (%)
PLife REIT	4.72	4.79	(1.5)
Jumbo	0.27	0.31	(12.9)

Source: Bloomberg, UOB Kay Hian

\*last price based on closing price on 31 Jan 22

**Singapore Research Team**  
+65 6535 6868  
research@uobkayhian.com

Sector	mom (% chg)	Recommendation	Top Buys	Analyst's Views
FSSTI	4.0			
Technology	(3.9)	OVERWEIGHT	Venture Corp	-
Plantation	3.6	UNDER WEIGHT	Wilmar	Dec 21 palm oil inventory came in way below market expectations. We believe this is mainly due bulk purchase of cooking oil as food aid for the flood victims and restocking ahead of Chinese New Year. We reckon that CPO prices would remain elevated due to the tight supply in 1Q22 and would start to correct later. Maintain UNDERWEIGHT on the back of lower earnings growth in 2022 and a downtrend in CPO prices.
Healthcare	(6.6)	OVERWEIGHT	Raffles Medical	-
Others	(2.3)	-	-	-
Finance	8.7	OVERWEIGHT	DBS, OCBC	Interest rates would be on an upcycle after QE Taper is completed by Mar 22. Our analysis indicates that every 100bp rise in 3M SIBOR results in NIM expansion of 25bp for DBS, 13bp for OCBC and 16bp for UOB. We raise our earnings forecasts for DBS and OCBC by 6% and 3% respectively for 2023 and expect earnings growth of 16% and 10% in 2024. BUY DBS (Target: S\$40.28) and OCBC (Target: S\$16.12) for 2023 dividend yield of 4.5% and 4.8% respectively. Maintain OVERWEIGHT.
Aviation	(0.3)	MARKET WEIGHT	ST Engineering	-
Property	2.7	OVERWEIGHT	City Devt	-
REITs	(5.8)	OVERWEIGHT	AREIT, LREIT, MINT	Existing VTLs have been kept open although capacity will be scaled down by half starting 21 Jan 22. Singapore has to weather a new wave of Omicron variant infections in 1Q22. We expect the reopening of borders with expansion of capacity for existing VTLs and introduction of new VTLs to resume in 2H22. BUY ART (Target: S\$1.29), CDREIT (Target: S\$1.42) and FEHT (Target: S\$0.74), which trade at discounts to NAV of 11%, 7% and 24% respectively. Maintain OVERWEIGHT.
Shipyard	6.1	OVERWEIGHT	Yangzijiang, Keppel Corp, SMM	The rig market appears to have turned a corner in 2021 with oil prices exceeding US\$80/bbl – this has resulted in stronger rig utilisation rates and a firming of rig dayrates vs 2020. The higher offshore activity expected in 2022 and 2023 underpins our positive view on the sector, especially given that meaningful rig supply was removed globally. We retain our OVERWEIGHT view on the sector, and our top picks remain Yangzijiang, Keppel Corp and Sembcorp Marine.
Media	Flat	-	-	-
Telecoms	3.5	OVERWEIGHT	Singtel	-
LandTransport	(2.9)	OVERWEIGHT	ComfortDelGro	-

Source: Bloomberg, UOB Kay Hian

**OUR TOP YIELD STOCK PICKS**

Company	Rec	Target Price (S\$)	Price 31 Jan 22 (S\$)	Upside (%)	Monthly Performance % Chg	PE 2021 (x)	PE 2022F (x)	Yield 2022F (%)
UtdHampshReitUSD	BUY	0.95	0.615	54.5	(7.5)	10.9	11.0	10.2
ManulifeReit USD	BUY	0.87	0.645	34.9	(3.7)	12.4	12.3	9.4
Sasseur REIT	BUY	1.05	0.795	32.1	(5.9)	9.8	9.5	9.1
KepPacOakReitUSD	BUY	1.10	0.74	48.6	(7.5)	15.7	11.8	8.5
EliteComREIT GBP	BUY	0.95	0.66	43.9	(0.8)	14.4	13.9	8.2

**OUR TOP LARGE MARKET CAPITALISATION STOCK PICKS**

Company	Rec	Target Price (S\$)	Price 31 Jan 22 (S\$)	Upside (%)	Monthly Performance % Chg	PE 2021 (x)	PE 2022F (x)	Yield 2022F (%)
Yangzijiang	BUY	2.00	1.29	55.0	(3.7)	7.6	5.8	5.3
Thai Beverage	BUY	0.92	0.655	40.5	(0.8)	15.6	15.4	3.2
SingTel	BUY	2.75	2.43	13.2	4.7	18.5	14.8	4.6
Aztech Global	BUY	1.55	0.845	83.4	(3.4)	8.8	7.2	6.5
Frasers Centerpoint	BUY	2.98	2.26	31.9	(2.2)	21.3	19.6	5.7
Ascendas Reit	BUY	3.83	2.76	38.8	(6.4)	18.0	17.0	5.9

**OUR TOP MID-SMALL MARKET CAPITALISATION STOCK PICKS**

Company	Rec	Target Price (S\$)	Price 31 Jan 22 (S\$)	Upside (%)	Monthly Performance % Chg	PE 2021 (x)	PE 2022F (x)	Yield 2022F (%)
BRC Asia	BUY	1.91	1.63	17.2	5.8	8.3	7.5	5.5
Civmec	BUY	0.98	0.625	56.8	(6.0)	9.0	8.0	3.8

Source: Bloomberg, UOB Kay Hian

**OUR INSTITUTIONAL RESEARCH COVERAGE**

CONTINUING TO HOLD RESEARCH COVERAGE									
Company	Rec	Target Price (S\$)	Price 31 Jan 22 (S\$)	Upside (%)	Monthly Performance % Chg	PE 2020 (x)	PE 2021F (x)	Yield 2021F (%)	Analyst's Views
★ AVIATION S I A	HOLD	4.85	5	(3.0)	0.2	n.a.	11.2	0.0	The opening up of the transatlantic travel market is the most significant development for international air travel since the start of the pandemic. This will pave the way for improved connectivity to other destinations. However, much of Asia and Australia still operate under travel restrictions. In valuing SIA, we have factored in a traffic recovery and have pegged valuation at 1.15x FY22/23 average adjusted book value. Maintain HOLD. Target price: S\$4.85.
SIA Engineering	HOLD	2.25	2.14	5.1	(1.8)	n.a.	24.7	2.8	
SATS	HOLD	4.09	3.91	4.6	0.5	124.4	40.9	2.6	
ST Engineering	BUY	4.05	3.73	8.6	(0.8)	23.1	21.5	4.0	
Sector						n.a.	16.1	1.9	
FINANCE									
DBS	BUY	40.28	35.2	14.4	7.8	13.3	13.5	4.0	
O C B C	BUY	16.12	12.47	29.3	9.4	11.2	10.9	4.2	
S'pore Exchange	HOLD	9.74	9.31	4.6	0.1	22.4	23.1	3.5	
Sector						15.6	15.8	3.9	
HEALTHCARE									
★ Raffles Medical	BUY	1.66	1.28	29.7	(6.6)	32.6	29.4	1.8	RFMD has been a beneficiary of the ongoing COVID-19 situation in Singapore. Inpatient volumes have already exceeded pre-COVID-19 levels due to a high domestic patient load. With nine new VTLs, RFMD stands to benefit from its exclusive contract with Changi Airport Group for on-arrival PCR testing. Operations in China are ramping up and are expected to break even in the coming years. Maintain BUY with a slightly higher target price of S\$1.66 (previously: S\$1.43).
Sector						32.6	29.4	1.8	
LAND TRANSPORT									
ComfortDelGro	BUY	1.99	1.4	42.1	2.2	18.5	13.5	5.0	
Sector						18.5	13.5	5.0	

**OUR INSTITUTIONAL RESEARCH COVERAGE**

FINANCIALS AND RESEARCH COVERAGE									
Company	Rec	Target Price (\$)	Price 31 Jan 22 (\$)	Upside (%)	Monthly Performance % Chg	PE 2020 (x)	PE 2021F (x)	Yield 2021F (%)	Analyst's Views
<b>MEDIA</b>									
★ S P H	Accept Offer	2.40	2.33	3.0	0.0	n.a.	21.1	5.7	Cuscaden announced that it had submitted an improved offer with a full cash offer of S\$2.36/share or cash-plus-share offer of S\$2.40/share for all of SPH's shares, at a consideration of around S\$3.9b. Both options are superior to Keppel's original cash-plus-share offer of S\$2.35/share. Barring any new offer, we recommend shareholders to ACCEPT the highest offer, which is currently Cuscaden's offer which provides higher consideration and price stability.
Sector						n.a.	21.1	5.7	
<b>PLANTATION</b>									
Bumitama	HOLD	0.65	0.55	18.2	1.9	11.1	10.9	2.9	Adani Wilmar (AWL) has finalised its IPO price range at Rs218-230 per share. We view this positively as it unlocks shareholder value by unleashing the true value of its subsidiary. However, we expect the impact from AWL to Wilmar to be marginal as the contribution of AWL is about 5% of Wilmar Group's earnings as compared with Yihai Kerry Arawana, which contributed 60-70%. We are not expecting any special dividend post listing of AWL. Maintain BUY. Target price: S\$6.00.
First Resources	HOLD	1.65	1.65	0.0	9.3	14.1	10.9	4.6	
★ Wilmar	BUY	6.00	4.27	40.5	3.1	11.8	11.3	3.5	
Sector						11.8	11.1	3.7	
<b>PROPERTY</b>									
★ CityDev	BUY	8.50	7.05	20.6	3.5	27.6	13.6	1.1	CDL reported a resilient operating performance in 3Q21 with strong sequential momentum in its property development and hospitality businesses. However, slight speed bumps may appear in the form of resurgent COVID-19 infections especially in Europe. Strategically, given the jettisoning of its stake in Sincere in Sep 21, the outlook appears reasonably good heading into 2022. Maintain BUY. Target price: S\$8.50.
Sector						27.6	13.6	1.1	
<b>SHIPYARD</b>									
★ Keppel Corp	BUY	6.94	5.65	22.8	10.4	10.1	12.1	3.3	KEP reported a very strong set of numbers for 2021 with all business segments registering improved performances yoy. With net debt down to a manageable 0.68x as at end-21, the outlook appears very favourable given our expectation for better economic conditions ahead, and continued progress in KEP's asset monetisation programme. Maintain BUY. Target price: S\$6.94.
Sembcorp Ind	BUY	2.59	2.28	13.6	14.0	13.2	11.5	2.6	
Sembcorp Marine	BUY	0.11	0.082	34.1	0.0	n.a.	n.a.	0.0	
★ Yangzijiang	BUY	2.00	1.29	55.0	(3.7)	7.6	5.8	5.3	YZJ announced that it is exploring the possibility of spinning off its investment business into a separate entity which will then be listed. While this process may take 6-12 months, we view this move in a positive light as it should remove some of the discounts that investors had arguably placed on the company, given the size of this non-core business. Maintain BUY. Target price: S\$2.00.
Sector						21.2	11.2	3.3	

**OUR INSTITUTIONAL RESEARCH COVERAGE**

Company	Rec	Target Price (\$)	Price 31 Jan 22 (\$)	Upside (%)	Monthly Performance % Chg	PE 2020 (x)	PE 2021F (x)	Yield 2021F (%)	Analyst's Views
<b>TECHNOLOGY</b>									
Sea Ltd USD	BUY	370.76	136.62	171.4	(38.9)	n.a.	n.a.	0.0	
Venture Corp	BUY	22.04	17.6	25.2	(3.9)	17.2	15.6	4.3	
Sector						<b>17.2</b>	<b>15.6</b>	<b>4.3</b>	
<b>TELECOMS</b>									
NetLink NBN Tr	HOLD	1.08	0.97	11.3	(3.0)	37.9	36.2	5.3	NetLink's 2QFY22 core net profit grew by 30% yoy and 12% qoq to S\$27.7m on higher NBAP and diversion revenue, as well as lower finance cost. This brings 1HFY22 core net profit to S\$52.5m (+17% yoy), in line with our estimates. Netlink declared 1HFY22 DPU of 2.56 S cents and we expect full-year DPU of 5.1 S cents. We downgrade the stock from BUY to HOLD as it is trading close to our DCF-based target price of S\$1.08. The stock offers sustainable dividend yield of 4.9% for FY22-24.
★ Singtel	BUY	2.75	2.43	13.2	4.7	18.5	14.8	4.6	There are green shots in terms of 5G uplift in Singapore and Australia as recent wins of additional spectrum will help drive the consumer business. Elsewhere, management is on track to achieve 170MW of data centre assets in the region (worth S\$7-8b). A 30MW integrated cable landing station and data centre is underway in Singapore as Singtel seeks financing options while the Thailand-Indonesia partnership remains in active discussions. Maintain BUY. Target price: S\$2.75.
StarHub	HOLD	1.30	1.29	0.8	(5.1)	15.5	13.7	4.7	
Sector						<b>19.3</b>	<b>15.6</b>	<b>4.6</b>	
<b>OTHERS</b>									
DairyFarm USD	BUY	3.60	2.67	34.8	(6.6)	32.8	16.5	6.2	
Genting SP	BUY	1.08	0.735	46.9	(5.2)	40.7	15.2	4.8	
★ Thai Beverage	BUY	0.92	0.655	40.5	(0.8)	15.6	15.4	3.2	THBEV announced reported FY21 core net profit of Bt27.3b, down 3.2% yoy but well within expectations. Total full-year dividend was at Bt0.50/share (FY20: Bt0.46). FY21 spirits and beer volumes softened by 1.8% and 11.2% yoy respectively, dragged down by COVID-19 lockdown restrictions in 4QFY21. The group continued to benefit from well-managed SG&A costs. Maintain BUY with the same target price of S\$0.92.
SingPost	HOLD	0.75	0.635	18.1	(2.3)	23.3	18.2	4.7	
Sector						<b>19.8</b>	<b>15.3</b>	<b>3.9</b>	

**Retail Market Monitor**

Thursday, 03 February 2022

**OUR INSTITUTIONAL RESEARCH COVERAGE**

Company	Rec	Target Price (\$)	Price 31 Jan 22 (\$)	Upside (%)	Monthly Performance % Chg	PE 2020 (x)	PE 2021F (x)	Yield 2021F (%)	Analyst's Views
<b>REITS</b>									
ARA LOGOS Log Tr	Accept Offer	1.07	0.825	29.7	(8.3)	22.1	12.6	6.6	
★ Ascendas Reit	BUY	3.83	2.76	38.8	(6.4)	18.0	17.0	5.9	1 Science Park Drive will be redeveloped into a life science and innovation campus comprising three Grade-A business park towers with column-free floor plates of more than 3,000sqm and an event plaza. AREIT owns 34% in the redevelopment based on its GFA contribution. On a stabilised basis, the 34% stake provides NPI yield of 6.3% post-transaction cost and increases pro forma 2020 DPU by 0.5%. AREIT provides 2022 distribution yield of 5.3%. Maintain BUY. Target price: S\$3.83.
Ascott Trust	BUY	1.29	1.02	26.5	(1.0)	n.a.	34.6	5.5	
CapLand IntCom T	BUY	2.39	1.94	23.2	(4.9)	19.9	18.6	5.9	
CDL Htrust	HOLD	1.42	1.13	25.7	(3.4)	56.3	35.7	3.1	
DigiCore Reit USD	BUY	1.08	1.17	(7.7)	0.9	35.7	36.1	3.9	
EliteComREIT GBP	BUY	0.95	0.66	43.9	(0.8)	14.4	13.9	8.2	
Far East HTrust	BUY	0.74	0.555	33.3	(5.9)	29.0	6.9	5.1	
★ Frasers Cpt Tr	BUY	2.98	2.26	31.9	(2.2)	21.3	19.6	5.7	FCT's retail occupancy improved 0.9ppt qoq to 97.3% in 4QFY21 while rental reversions were mildly negative at 0.6% in FY21. Tenant sales recovered to 98% of pre-COVID-19 levels in September. FCT divested of Bedok Point, Anchorpoint and YewTee Point to refocus on dominant suburban malls. It is well positioned to pursue acquisitions after lowering aggregate leverage to 33.3% as of end-Sep 21. Maintain BUY for its defensive distribution yield of 5.6% for FY22. Target price: S\$2.98.
★ Frasers L&C Tr	BUY	1.79	1.37	30.7	(9.9)	38.6	19.6	5.6	FLT benefitted from the acquisition of six European properties completed on 24 May 21 which provided more than four months of contributions. Cost of borrowings improved 0.3ppt yoy and 0.1ppt qoq to 1.6% due to lower base rates and lower interest rates for borrowings refinanced in 2HFY21. Valuation uplift was 9% or S\$603.9m and NAV per unit increased 12.7% yoy to S\$1.24. Distribution yield is attractive at 5.1% for FY22 and 5.2% for FY23. Maintain BUY. Target price: S\$1.79.
Keppel REIT	BUY	1.52	1.12	35.7	(0.9)	27.4	19.2	5.2	
KepPacOakReitUSD	BUY	1.10	0.74	48.6	(7.5)	15.7	11.8	8.5	
Lendlease REIT	BUY	1.03	0.82	25.6	(8.4)	33.9	22.0	5.7	
ManulifeReit USD	BUY	0.87	0.645	34.9	(3.7)	12.4	12.3	9.4	
MapletreeCom	BUY	2.48	1.8	37.8	(10.0)	22.6	19.4	5.6	
MapletreeInd	BUY	3.72	2.51	48.2	(7.4)	17.4	16.5	6.0	
MapletreeLog	HOLD	2.08	1.69	23.1	(11.1)	20.7	21.7	5.1	
PLife REIT	HOLD	4.72	4.79	(1.5)	(6.6)	34.7	32.5	3.1	
Sasseur Reit	BUY	1.05	0.795	32.1	(5.9)	9.8	9.5	9.1	
Suntec REIT	BUY	1.74	1.52	14.5	0.7	28.1	22.5	6.0	
UtdHampshReitUSD	BUY	0.95	0.615	54.5	(7.5)	10.9	11.0	10.2	
Sector						24.5	19.7	6.2	

If year-end is before June, earnings are shown in the previous period

## Retail Market Monitor

Thursday, 03 February 2022

### OUR RETAIL RESEARCH COVERAGE

Company	Rec	Target Price (\$)	Price 31 Jan 22 (\$)	Upside (%)	Monthly Performance % Chg	PE 2020 (x)	PE 2021F (x)	Yield 2021F (%)	Analyst's Views
Aoxin Q & M	BUY	0.37	0.24	54.2	0.0	n.a.	10.2	3.5	
APAC Realty	HOLD	0.41	0.645	(36.4)	(10.4)	15.7	15.5	3.3	
★ Aztech Global	BUY	1.55	0.845	83.4	(3.4)	8.8	7.2	6.5	We think Aztech's share price correction of >30% since its IPO in Mar 21 is overdone. It has been delivering solid results (9M21 earnings grew 55% yoy) and we expect 2021/22 earnings to grow 33/22% yoy. We understand that Aztech's operations remain intact and orderbook remains healthy. We reduced our 2022 EPS by 9% to reflect a more conservative view. Our target price fell 9% to S\$1.55, pegged to peers' average of 13.3x 2022F PE. Maintain BUY. Target price: S\$1.55.
BRC Asia	BUY	1.91	1.63	17.2	5.8	8.3	7.5	5.5	
Centurion	BUY	0.43	0.325	32.3	(1.5)	12.2	6.8	6.2	
ChinaSunsine	BUY	0.695	0.465	49.5	(4.1)	4.8	5.2	3.7	
★ Civmec	BUY	0.98	0.625	56.8	(6.0)	9.0	8.0	3.8	Civmec's 1QFY22 net profit of A\$11m (+62% yoy) was slightly above our expectations, at 26% of our full-year estimate. Civmec remains positive on its future outlook given the robust and growing orderbook, which has increased 21% yoy to A\$1.15b. In addition, Civmec sees a strong pipeline of tendering opportunities across all the sectors it operates in, with emerging opportunities in new sectors including battery minerals, rare earths and hydrogen plants.
CSE Global	BUY	0.59	0.475	24.2	(4.0)	10.5	9.1	5.8	
Food Empire	BUY	1.30	0.665	95.5	(13.6)	10.6	8.5	3.5	
Frecken	BUY	2.06	1.64	25.6	(16.8)	11.6	10.4	2.9	
Fu Yu	BUY	0.32	0.27	18.5	(3.6)	10.9	10.2	5.9	
GHY Culture	BUY	1.05	0.5	110.0	(9.9)	15.7	9.1	3.3	
Ho Bee Land	BUY	3.32	2.8	18.6	0.4	10.3	11.6	3.6	
Hong Leong Asia	BUY	1.38	0.81	70.4	(4.1)	8.5	7.1	2.3	
iFAST	BUY	9.75	6.24	56.3	(25.7)	53.4	44.8	0.6	
InnoTek	BUY	1.20	0.685	75.2	(11.0)	8.7	6.8	4.4	
ISOTeam	BUY	0.30	0.108	177.8	(15.0)	3.6	3.4	7.4	
Japfa	HOLD	0.60	0.615	(2.4)	1.7	7.2	7.5	1.6	
Jiutian Chemical	BUY	0.138	0.086	60.5	13.2	2.9	4.0	0.0	
Jumbo	SELL	0.27	0.31	(12.9)	(1.6)	44.7	20.8	3.4	
Kimly	BUY	0.36	0.41	(12.2)	(1.2)	12.4	16.0	3.2	
MarcoPolo Marine	BUY	0.038	0.027	40.7	0.0	6.4	15.8	0.0	
Micro-Mech	SELL	2.87	3.31	(13.3)	(2.1)	28.1	24.3	3.6	
MM2 Asia	BUY	0.095	0.052	82.7	2.0	n.a.	8.5	0.0	
Nanofilm	HOLD	2.67	2.83	(5.7)	(25.9)	28.6	23.3	0.9	
Oxley	BUY	0.28	0.181	54.7	(3.7)	58.4	4.0	5.8	
PropNex	BUY	2.17	1.61	34.8	(4.7)	9.5	11.2	6.8	
Q&M Dental	BUY	0.78	0.57	37.4	(5.8)	13.6	12.2	7.0	
Rex	BUY	0.46	0.335	37.3	9.8	6.5	8.3	0.0	
Riverstone	HOLD	0.68	0.705	(3.5)	0.7	2.3	6.4	12.4	
Sheng Siong	HOLD	1.58	1.49	6.0	2.1	17.2	19.8	3.6	

Source: Bloomberg, UOB Kay Hian

**OUR RETAIL RESEARCH COVERAGE**

Company	Rec	Target Price (S\$)	Price 31 Jan 22 (S\$)	Upside (%)	Monthly Performance % Chg	PE 2020 (x)	PE 2021F (x)	Yield 2021F (%)	Analyst's Views
SingMedical	BUY	0.48	0.29	65.5	(4.9)	10.5	8.8	3.4	TCA is a premium automobile dealership group mainly operating in China's affluent Greater Bay Area. The company carries well-established automobile brands such as BMW and McLaren, riding on the strong demand for premium automobiles and the line-up of electric vehicles slated for launch. Initiate coverage with BUY and a target price of S\$0.39.
ST Group Food	BUY	0.14	0.139	0.7	2.2	14.3	8.7	3.4	
Sunpower	BUY	1.03	0.425	142.4	(11.5)	7.2	4.8	0.8	
★ TC Auto	BUY	0.39	0.255	52.9	(5.6)	4.8	3.9	0.0	
Tianjin ZX USD	BUY	1.25	1.1	13.6	(4.3)	7.2	6.4	4.7	
UMS Holdings	BUY	1.66	1.2	38.3	(21.1)	13.0	11.0	2.7	
Uni-Asia	BUY	2.34	1.12	108.9	(8.9)	3.8	3.3	5.4	
UnUsUaL	HOLD	0.135	0.125	8.0	1.6	20.9	13.7	0.0	
Valuetronics	HOLD	0.52	0.525	(1.0)	(3.7)	13.2	12.2	3.3	
Wing Tai	BUY	2.04	1.76	15.9	(1.7)	44.1	18.2	1.7	

Source: Bloomberg, UOB Kay Hian



## Disclosures/Disclaimers

This report is prepared by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser in Singapore.

This report is provided for information only and is not an offer or a solicitation to deal in securities or to enter into any legal relations, nor an advice or a recommendation with respect to such securities.

**This report is prepared for general circulation.** It does not have regard to the specific investment objectives, financial situation and the particular needs of any recipient hereof. Advice should be sought from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before the person makes a commitment to purchase the investment product.

This report is confidential. This report may not be published, circulated, reproduced or distributed in whole or in part by any recipient of this report to any other person without the prior written consent of UOBKH. This report is not directed to or intended for distribution to or use by any person or any entity who is a citizen or resident of or located in any locality, state, country or any other jurisdiction as UOBKH may determine in its absolute discretion, where the distribution, publication, availability or use of this report would be contrary to applicable law or would subject UOBKH and its connected persons (as defined in the Financial Advisers Act, Chapter 110 of Singapore) to any registration, licensing or other requirements within such jurisdiction.

The information or views in the report ("Information") has been obtained or derived from sources believed by UOBKH to be reliable. However, UOBKH makes no representation as to the accuracy or completeness of such sources or the Information and UOBKH accepts no liability whatsoever for any loss or damage arising from the use of or reliance on the Information. UOBKH and its connected persons may have issued other reports expressing views different from the Information and all views expressed in all reports of UOBKH and its connected persons are subject to change without notice. UOBKH reserves the right to act upon or use the Information at any time, including before its publication herein.

Except as otherwise indicated below, (1) UOBKH, its connected persons and its officers, employees and representatives may, to the extent permitted by law, transact with, perform or provide broking, underwriting, corporate finance-related or other services for or solicit business from, the subject corporation(s) referred to in this report; (2) UOBKH, its connected persons and its officers, employees and representatives may also, to the extent permitted by law, transact with, perform or provide broking or other services for or solicit business from, other persons in respect of dealings in the securities referred to in this report or other investments related thereto; (3) the officers, employees and representatives of UOBKH may also serve on the board of directors or in trustee positions with the subject corporation(s) referred to in this report. (All of the foregoing is hereafter referred to as the "Subject Business"); and (4) UOBKH may otherwise have an interest (including a proprietary interest) in the subject corporation(s) referred to in this report.

As of the date of this report, no analyst responsible for any of the content in this report has any proprietary position or material interest in the securities of the corporation(s) which are referred to in the content they respectively author or are otherwise responsible for.

## IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by UOBKH, a company authorized, as noted above, to engage in securities activities in Singapore. UOBKH is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution by UOBKH (whether directly or through its US registered broker dealer affiliate named below) to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). All US persons that receive this document by way of distribution from or which they regard as being from UOBKH by their acceptance thereof represent and agree that they are a major institutional investor and understand the risks involved in executing transactions in securities.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through UOB Kay Hian (U.S.) Inc ("UOBKHUS"), a registered broker-dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through UOBKH.

UOBKHUS accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to and intended to be received by a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of UOBKHUS and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

### Analyst Certification/Regulation AC

Each research analyst of UOBKH who produced this report hereby certifies that (1) the views expressed in this report accurately reflect his/her personal views about all of the subject corporation(s) and securities in this report; (2) the report was produced independently by him/her; (3) he/she does not carry out, whether for himself/herself or on behalf of UOBKH or any other person, any of the Subject Business involving any of the subject corporation(s) or securities referred to in this report; and (4) he/she has not received and will not receive any compensation that is directly or indirectly related or linked to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. However, the compensation received by each such research analyst is based upon various factors, including UOBKH's total revenues, a portion of which are generated from UOBKH's business of dealing in securities.

Reports are distributed in the respective countries by the respective entities and are subject to the additional restrictions listed in the following table.

General	This report is not intended for distribution, publication to or use by any person or entity who is a citizen or resident of or located in any country or jurisdiction where the distribution, publication or use of this report would be contrary to applicable law or regulation.
Hong Kong	This report is distributed in Hong Kong by UOB Kay Hian (Hong Kong) Limited ("UOBKHHK"), which is regulated by the Securities and Futures Commission of Hong Kong. Neither the analyst(s) preparing this report nor his associate, has trading and financial interest and relevant relationship specified under Para. 16.4 of Code of Conduct in the listed corporation covered in this report. UOBKHHK does not have financial interests and business relationship specified under Para. 16.5 of Code of Conduct with the listed corporation covered in this report. Where the report is distributed in Hong Kong and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKHHK (and not the relevant foreign research house) in Hong Kong in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Hong Kong who is not a professional investor, or institutional investor, UOBKHHK accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Indonesia	This report is distributed in Indonesia by PT UOB Kay Hian Sekuritas, which is regulated by Financial Services Authority of Indonesia (OJK). Where the report is distributed in Indonesia and contains research analyses or reports from a foreign research house, please note recipients of the analyses or reports are to contact PT UOBKH (and not the relevant foreign research house) in Indonesia in respect of any matters arising from, or in connection with, the analysis or report.
Malaysia	Where the report is distributed in Malaysia and contains research analyses or reports from a foreign research house, the recipients of the analyses or reports are to contact UOBKHM (and not the relevant foreign research house) in Malaysia, at +603-21471988, in respect of any matters arising from, or in connection with, the analysis or report as UOBKHM is the registered person under CMSA to distribute any research analyses in Malaysia.
Singapore	This report is distributed in Singapore by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser regulated by the Monetary Authority of Singapore. Where the report is distributed in Singapore and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKH (and not the relevant foreign research house) in Singapore in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, UOBKH accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Thailand	This report is distributed in Thailand by UOB Kay Hian Securities (Thailand) Public Company Limited, which is regulated by the Securities and Exchange Commission of Thailand.
United Kingdom	This report is being distributed in the UK by UOB Kay Hian (U.K.) Limited, which is an authorised person in the meaning of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in the UK is intended only for institutional clients.
United States of America ('U.S.')	This report cannot be distributed into the U.S. or to any U.S. person or entity except in compliance with applicable U.S. laws and regulations. It is being distributed in the U.S. by UOB Kay Hian (US) Inc, which accepts responsibility for its contents. Any U.S. person or entity receiving this report and wishing to effect transactions in any securities referred to in the report should contact UOB Kay Hian (US) Inc. directly.

Copyright 2022, UOB Kay Hian Pte Ltd. All rights reserved.

<http://research.uobkayhian.com>

RCB Regn. No. 197000447W